|
gptkbp:instanceOf
|
gptkb:synthetic_progestin
gptkb:drug
|
|
gptkbp:approvedBy
|
1971 (US)
|
|
gptkbp:ATCCode
|
L02AB01
|
|
gptkbp:availableOn
|
gptkb:tablet
oral suspension
|
|
gptkbp:brand
|
Megace
Megace ES
Megace OS
|
|
gptkbp:CASNumber
|
595-33-5
|
|
gptkbp:category
|
gptkb:antineoplastic_agent
gptkb:progestogen
appetite stimulant
|
|
gptkbp:chemicalClass
|
pregnane steroid
|
|
gptkbp:contraindication
|
pregnancy
hypersensitivity
|
|
gptkbp:developedBy
|
gptkb:Squibb
|
|
gptkbp:discoveredIn
|
1960s
|
|
gptkbp:eliminationHalfLife
|
20-50 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C24H32O4
|
|
gptkbp:IUPACName
|
17-acetyloxy-6-methylpregna-4,6-diene-3,20-dione
|
|
gptkbp:KEGGID
|
D00423
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
progestogenic activity
glucocorticoid activity
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
X (contraindicated)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1423
38244
41926
DB00351
|
|
gptkbp:relatedTo
|
gptkb:medroxyprogesterone_acetate
megestrol
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
edema
hypertension
weight gain
hyperglycemia
thromboembolism
|
|
gptkbp:UNII
|
EA6LD1M70M
|
|
gptkbp:usedFor
|
cachexia
appetite stimulation
palliative treatment of advanced breast cancer
palliative treatment of endometrial cancer
treatment of anorexia
weight loss in AIDS patients
|
|
gptkbp:bfsParent
|
gptkb:medroxyprogesterone_acetate
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
megestrol acetate
|